Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).

被引：0
|
作者：
Weinstock, Chana
Bandaru, Pradeep
Fernandes, Laura L.
Chang, Elaine
Girvin, Andrew
Tang, Shenghui
Agrawal, Sundeep
Suzman, Daniel L.
Singh, Harpreet
Brave, Michael Holman
Xu, James
Goldberg, Kirsten B.
Ibrahim, Amna
Theoret, Marc Robert
Pazdur, Richard
Beaver, Julia A.
机构：
[1] US FDA, Silver Spring, MD USA
[2] Palantir Technol, Washington, DC USA
[3] Palantir Technol, Menlo Pk, CA USA
[4] Medstar Washington Hosp Ctr, Washington, DC USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] US FDA, Washington, DC USA
[7] NCI, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5045
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
    Shabto, Julie M.
    Martini, Dylan J.
    Liu, Yuan
    Ravindranathan, Deepak
    Brown, Jacqueline
    Hitron, Emilie E.
    Russler, Greta A.
    Caulfield, Sarah
    Kissick, Haydn
    Alemozaffar, Mehrdad
    Ogan, Kenneth
    Harris, Wayne B.
    Master, Viraj A.
    Kucuk, Omer
    Carthon, Bradley C.
    Bilen, Mehmet A.
    CANCER MEDICINE, 2020, 9 (08): : 2752 - 2760
  • [42] Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
    Xiang, Jing
    Liu, Xueni
    Hao, Yue
    Zhu, Yanyan
    Wu, Minhua
    Lou, Jian
    Wang, Yonghui
    Xu, Chunwei
    Xie, Yanru
    Huang, Jianhui
    TRANSLATIONAL ONCOLOGY, 2023, 38
  • [43] Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).
    Agarwal, Archana
    Nassar, Amin
    Pond, Gregory Russell
    Barletta, Justine A.
    Acosta, Andres
    Abou Alaiwi, Sarah
    Curran, Catherine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [44] Immune Checkpoint Inhibitors Effective in Urothelial Cancer
    Brower, Vicki
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (05):
  • [45] Real-world evidence of the impact of prior antibiotic exposure on immune checkpoint inhibitor outcomes in patients with metastatic urothelial cancer
    Hoffman-Censits, Jean H.
    Harshman, Lauren Christine
    Metcalf, Meredith
    Abou Alaiwi, Sarah
    Meyer, Craig S.
    Yang, Erru
    Satram, Sacha
    Ogale, Sarika
    Faber, Kathleene
    Ma, Esprit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Changes in circulating tumor DNA (ctDNA) and outcomes in solid tumors treated with immune checkpoint inhibitors (ICIs)
    Al-Showbaki, Laith
    Iafolla, Marco
    Tamimi, Faris
    Molto, Consolacion
    Mittal, Abhenil
    Cescon, David W.
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
    Huang, Xuan-Zhang
    Gao, Peng
    Song, Yong-Xi
    Xu, Yan
    Sun, Jing-Xu
    Chen, Xiao-Wan
    Zhao, Jun-Hua
    Wang, Zhen-Ning
    ONCOIMMUNOLOGY, 2019, 8 (12):
  • [48] Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
    Ohm, Hyejee
    Abdel-Rahman, Omar
    CURRENT ONCOLOGY, 2023, 30 (01) : 786 - 802
  • [49] Beneficial Effect of Antibiotic Use in Patients with Stage IV NSCLC Treated with Immune Checkpoint Inhibitors
    Wang, F.
    Al-Jumayli, M.
    D'Rummo, K.
    Pei, L.
    Huang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1140 - S1140
  • [50] Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data
    Hong, Soojung
    Lee, Ju Hyun
    Heo, Ja Yoon
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Yu Jung
    Kim, Jee Hyun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)
12345